Integra LifeSciences lowers revenue and earnings outlook for 2026

Health Medical Technology & Services Edited by: Angela Harmantas 11:44 Fri 02 Oct 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Integra Lifesciences Holdings Corp ( NASDAQ:IART ) View Price & Profile Integra LifeSciences lowers revenue and earnings outlook for 2026 Last updated: 11:44 02 Oct 2026 EDT, First published: 10:44 02 Oct 2026 EDT Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion. Alongside that reduction, it lowered adjusted earnings per diluted share guidance to $2.30 to $2.40 from $2.40 to $2.50. Those revisions reflect updated assumptions about both the flooding's impact and the broader business for the remainder of 2026. Preliminary, unaudited third-quarter estimates put revenue at approximately $410 million to $412 million and adjusted earnings per diluted share at $0.55 to $0.59, pending financial closing. Despite the cuts, CEO Stuart Essig expects operating cash flow above $85 million for the quarter and approximately $190 million to $200 million for the year. Essig also highlighted improving product availability, key products returning to market, and stronger commercial execution across the broader business. At Cincinnati, however, Integra estimates flood-related supply disruption reduced third-quarter revenue by approximately $7 million and expects a $15 million to $20 million fourth-quarter hit. To support customers, the company has tapped inventory and alternate suppliers for certain products while restoring the facility, which supports its Specialty Surgical Technologies portfolio. It also expects property and business interruption insurance recoveries to cushion much of the disruption's earnings impact throughout the recovery period. Integra expects full manufacturing operations at Cincinnati to resume during the second quarter of 2027. Shares of Integra Lifesciences dropped 20.6% on Friday. Continue reading